Serina Therapeutics Announces Board and Executive Changes
Ticker: SER · Form: 8-K · Filed: Aug 16, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $650, $60 million, $120,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Serina Therapeutics (SERN) board shakeup and exec comp changes filed. Watch for new strategy.
AI Summary
Serina Therapeutics, Inc. announced on August 12, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans. This follows the company's previous name change from AgeX Therapeutics, Inc. on June 6, 2017.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect the company's direction and stability.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- AgeX Therapeutics, Inc. (company) — Former company name
- August 12, 2024 (date) — Date of earliest event reported
- June 6, 2017 (date) — Date of former company name change
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates a departure of certain officers and directors, but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing states that directors have been elected, but their names are not provided in this excerpt.
What are the key changes in the compensatory arrangements for certain officers?
The filing mentions updates to compensatory arrangements, but the specific details of these changes are not elaborated in this section.
When did Serina Therapeutics, Inc. change its name from AgeX Therapeutics, Inc.?
Serina Therapeutics, Inc. changed its name from AgeX Therapeutics, Inc. on June 6, 2017.
What is the principal executive office address for Serina Therapeutics, Inc.?
The principal executive office is located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-15 17:54:20
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
- $650 — an's services will be paid at a rate of $650 per hour. Mr. Curhan was also awarded a
- $60 million — ompany or the Company's completion of a $60 million equity transaction. There are no fami
- $120,000 — icipant and the amount involved exceeds $120,000, and in which Mr. Curhan had or will ha
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-032700.txt ( ) — 212KB
- ser-20240812.xsd (EX-101.SCH) — 3KB
- ser-20240812_lab.xml (EX-101.LAB) — 34KB
- ser-20240812_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: August 15, 2024 By: /s/ Steve Ledger Interim Chief Executive Officer